3月24日 - ** Cryoport CYRX.O股价大涨 23.2% 至 7 美元
** CYRX 为生命科学公司提供供应链解决方案
** 瑞银将 CYRX 的评级从 "中性 "上调至 "买入"
** CYRX 的 MVE 子公司面临的逆风和更广泛的生物制药市场疲软压低了销售额，但这些挑战已得到很好的理解，似乎正在趋于稳定，并提供了一个有吸引力的切入点 - UBS
** 券商预计 Cryoport 将在 2027 年实现正的自由现金流
** 细胞和基因治疗服务产品的规模不断扩大，为实现低两位数以上的(~10+) 中长期销售增长和正自由现金流提供了可靠的途径 - UBS
** 截至上次收盘，CYRX 的年累计跌幅约为 27
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.